Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 6

Emerging biomarker for predicting acute kidney injury after cardiac surgery: cystatin C

Pages
1096–1103
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our study, serum CysC was a reliable biomarker that may aid in the earlydetection and follow-up of AKI after cardiac surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Cardiopulmonary bypass (CPB)-associated acute kidney injury (AKI) is a common situation and rapid diagnosisand risk classification are important in the prevention and management of AKI.
📊
Key Findings & Data:Changes in serum creatinine (SCr) levels in the currentconsensus criteria do not allow clinicians to diagnose CPB-associated AKI until 48 h after surgery.Materials and methods: We conducted a prospective single center study involving 57 patients who underwent cardiac surgery withCBP to compare serum beta-trace protein (BTP), neutrophil gelatinase-associated lipocalin-2 (NGAL), and cystatin C (CysC) levelswith SCr for early diagnosis of CPB associated AKI.
💡
Conclusion & Impact:According to our study, serum CysC was a reliable biomarker that may aid in the earlydetection and follow-up of AKI after cardiac surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Cardiopulmonary bypass (CPB)-associated acute kidney injury (AKI) is a common situation and rapid diagnosisand risk classification are important in the prevention and management of AKI. Changes in serum creatinine (SCr) levels in the currentconsensus criteria do not allow clinicians to diagnose CPB-associated AKI until 48 h after surgery.Materials and methods: We conducted a prospective single center study involving 57 patients who underwent cardiac surgery withCBP to compare serum beta-trace protein (BTP), neutrophil gelatinase-associated lipocalin-2 (NGAL), and cystatin C (CysC) levelswith SCr for early diagnosis of CPB associated AKI. We defined AKI according to KDIGO criteria.Results: AKI was diagnosed in 24 (42.1%) patients. Mean duration of postoperative intensive care unit stay was 4.79 (± 6.12) days for theAKI+ group and 2.15 (± 0.56) days for the AKI– group. The average length of hospital stay was 8.13 (± 5.75) days for the AKI+ group and7.21 (± 3.68) days for the AKI– group, which was significantly longer in the AKI+ group (P < 0.001, P = 0.011). Unlike other biomarkers,a significant increase in postoperative CysC levels was always found in patients with AKI during follow-up when compared to patientsin whom AKI did not develop (P < 0.001).Conclusion: Increase in serum CysC levels showed a significant positive correlation with increase in SCr levels. We have not seen thiscorrelation between other biomarkers and SCr. According to our study, serum CysC was a reliable biomarker that may aid in the earlydetection and follow-up of AKI after cardiac surgery.

🔖

Cite This Article

ARICI, M., YILMAZ, M., DOĞAN, R., PAŞAOĞLU, İ., TÜRKMEN, E., SAYDAM, O., PORTAKAL, O., DEMİRCİN, M. (2022). Emerging biomarker for predicting acute kidney injury after cardiac surgery: cystatin C. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 6, 1096–1103. https://ajindex.com/articles/610367

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1: 19-32.
  2. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11: R31. Acute Kidney Injury Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter, Suppl 2012; 2: 1-138.
  3. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med 2004; 30: 33-37.
  4. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, Burns A, Sweny P, Burroughs AK. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978.
  5. Gaygisiz U, Aydogdu M, Badoglu M, Boyaci N, Gullu Z, Gursel G. Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients? Scand J Clin Lab Invest 2016: 1-8.
  6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
  7. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K. Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 1999; 45: 567-568.
  8. Bökenkamp A, Franke I, Schlieber M, Düker G, Schmitt J, Buderus S, Lentze MJ, Stoffel-Wagner B. Beta-trace protein— a marker of kidney function in children: “Original research communication-clinical investigation”. Clin Biochem 2007; 40: 969-975.
  9. Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A, Mild, Moderate Kidney Disease Study Group. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 2010; 56: 740-749.
  10. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-2543.
  11. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307-315.
  12. Wagener G, Gubitosa G, Wang S, Bo